

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Finasteride (3.25%) Formulation

Version 1.14      Revision Date: 2024/04/06      SDS Number: 2160725-00015      Date of last issue: 2023/09/30  
Date of first issue: 2017/11/09

### 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Finasteride (3.25%) Formulation

#### Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor  
Jersey City, New Jersey, U.S.A 07302

Telephone : +1-551-430-6000

Emergency telephone number : +1-215-631-6999

E-mail address : EHSSTEWARD@organon.com

#### Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

Restrictions on use : Not applicable

### 2. HAZARDS IDENTIFICATION

#### Emergency Overview

**Appearance** : solid  
**Colour** : blue  
**Odour** : odourless

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. Toxic to aquatic life with long lasting effects.

#### GHS Classification

Reproductive toxicity : Category 1B

Specific target organ toxicity - repeated exposure : Category 2

Long-term (chronic) aquatic hazard : Category 2

#### GHS label elements

Hazard pictograms :



Signal word : Danger

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version 1.14      Revision Date: 2024/04/06      SDS Number: 2160725-00015      Date of last issue: 2023/09/30  
Date of first issue: 2017/11/09

Hazard statements : H360D May damage the unborn child.  
H373 May cause damage to organs through prolonged or repeated exposure.  
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**  
P201 Obtain special instructions before use.  
P202 Do not handle until all safety precautions have been read and understood.  
P260 Do not breathe dust/ fume/ gas/ mist/ vapours/ spray.  
P273 Avoid release to the environment.  
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

**Response:**

P308 + P313 IF exposed or concerned: Get medical advice/ attention.  
P391 Collect spillage.

**Storage:**

P405 Store locked up.

**Disposal:**

P501 Dispose of contents/ container to an approved waste disposal plant.

**Physical and chemical hazards**

Not classified based on available information.

**Health hazards**

May damage the unborn child. May cause damage to organs through prolonged or repeated exposure.

**Environmental hazards**

Toxic to aquatic life with long lasting effects.

**Other hazards which do not result in classification**

None known.

### 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

**Components**

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 1 -< 10
Starch	9005-25-8	>= 1 -< 10
Finasteride	98319-26-7	>= 2.5 -< 10

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
1.14	2024/04/06	2160725-00015	2023/09/30
			Date of first issue: 2017/11/09

### 4. FIRST AID MEASURES

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention.
- In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : Flush eyes with water as a precaution.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention.  
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May damage the unborn child.  
May cause damage to organs through prolonged or repeated exposure.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.

### 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides  
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

### 6. ACCIDENTAL RELEASE MEASURES

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue:
1.14	2024/04/06	2160725-00015	2023/09/30
			Date of first issue: 2017/11/09

---

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

---

## 7. HANDLING AND STORAGE

### Handling

- Technical measures : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust, fume, gas, mist, vapours or spray.  
Do not swallow.  
Avoid contact with eyes.  
Wash skin thoroughly after handling.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Keep container tightly closed.  
Do not eat, drink or smoke when using this product.  
Take care to prevent spills, waste and minimize release to the environment.
- Avoidance of contact : Oxidizing agents

### Storage

- Conditions for safe storage : Keep in properly labelled containers.  
Store locked up.  
Keep tightly closed.  
Store in accordance with the particular national regulations.
- Materials to avoid : Do not store with the following product types:  
Strong oxidizing agents
- Packaging material : Unsuitable material: None known.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version 1.14      Revision Date: 2024/04/06      SDS Number: 2160725-00015      Date of last issue: 2023/09/30  
Date of first issue: 2017/11/09

### 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

#### Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	PC-TWA	10 mg/m <sup>3</sup>	CN OEL
		TWA	10 mg/m <sup>3</sup>	ACGIH
Starch	9005-25-8	TWA	10 mg/m <sup>3</sup>	ACGIH
Finasteride	98319-26-7	TWA	0.5 µg/m <sup>3</sup> (OEB 5)	Internal
		Wipe limit	5 µg/100 cm <sup>2</sup>	Internal

**Engineering measures** : Use closed processing systems or containment technologies to control at source (e.g., glove boxes/isolators) and to prevent leakage of compounds into the workplace. All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. No open handling permitted. Totally enclosed processes and materials transport systems are required. Operations require the use of appropriate containment technology designed to prevent leakage of compounds into the workplace.

#### Personal protective equipment

**Respiratory protection** : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

**Eye/face protection** : Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.

**Skin and body protection** : Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.

**Hand protection**

Material : Chemical-resistant gloves

Remarks : Consider double gloving.

**Hygiene measures** : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the work-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version 1.14	Revision Date: 2024/04/06	SDS Number: 2160725-00015	Date of last issue: 2023/09/30 Date of first issue: 2017/11/09
-----------------	------------------------------	------------------------------	---

---

ing place.

When using do not eat, drink or smoke.

Wash contaminated clothing before re-use.

The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

---

### 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	solid
Colour	:	blue
Odour	:	odourless
Odour Threshold	:	No data available
pH	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	Not applicable
Flammability (solid, gas)	:	Not classified as a flammability hazard
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapour pressure	:	Not applicable
Relative vapour density	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Solubility(ies) Water solubility	:	No data available
Partition coefficient: n-	:	Not applicable

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

octanol/water

Auto-ignition temperature : No data available

Decomposition temperature : No data available

Viscosity

    Viscosity, kinematic : Not applicable

Explosive properties : Not explosive

Oxidizing properties : The substance or mixture is not classified as oxidizing.

Particle characteristics

Particle size : No data available

### 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.

Chemical stability : Stable under normal conditions.

Possibility of hazardous reactions : Can react with strong oxidizing agents.

Conditions to avoid : None known.

Incompatible materials : Oxidizing agents

Hazardous decomposition products : No hazardous decomposition products are known.

### 11. TOXICOLOGICAL INFORMATION

Exposure routes : Skin contact  
Ingestion  
Eye contact

#### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg  
Method: Calculation method

#### Components:

##### Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l  
Exposure time: 4 h  
Test atmosphere: dust/mist

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

---

### Starch:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg  
Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

### Finasteride:

Acute oral toxicity : LD50 (Rat): 373 - 828 mg/kg  
LD50 (Mouse): 486 mg/kg

### Skin corrosion/irritation

Not classified based on available information.

### Components:

#### Finasteride:

Species : Rabbit  
Result : No skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Starch:

Species : Rabbit  
Result : No eye irritation

#### Finasteride:

Species : Rabbit  
Remarks : slight irritation

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

### Components:

#### Starch:

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative



# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

---

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### **Cellulose:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Mammalian erythrocyte micronucleus test (in vivo  
cytogenetic assay)  
Species: Mouse  
Application Route: Ingestion  
Result: negative

##### **Starch:**

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

##### **Finasteride:**

Genotoxicity in vitro : Test Type: Chromosome aberration test in vitro  
Result: positive

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Alkaline elution assay  
Result: negative

Genotoxicity in vivo : Test Type: Mutagenicity (in vivo mammalian bone-marrow  
cytogenetic test, chromosomal analysis)  
Application Route: Oral  
Result: negative

### Carcinogenicity

Not classified based on available information.

#### Components:

##### **Cellulose:**

Species : Rat  
Application Route : Ingestion

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

---

Exposure time : 72 weeks  
Result : negative

### Finasteride:

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
: 160 mg/kg body weight  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

Species : Mouse  
Application Route : Ingestion  
Exposure time : 19 month(s)  
Result : negative  
Target Organs : Testes  
Remarks : Benign tumor(s)

### Reproductive toxicity

May damage the unborn child.

### Components:

#### Cellulose:

Effects on fertility : Test Type: One-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Result: negative

#### Finasteride:

Effects on fertility : Test Type: Fertility/early embryonic development  
Species: Rabbit  
Application Route: Oral  
Fertility: NOAEL: 80 mg/kg body weight  
Result: No effects on fertility

Test Type: Fertility/early embryonic development  
Species: Rat  
Application Route: Ingestion  
Fertility: LOAEL: 80 mg/kg body weight  
Result: positive  
Remarks: There is no evidence that these findings are relevant to humans.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

---

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 0.003 mg/kg body weight  
Result: Teratogenic effects, Embryotoxic effects.

Test Type: Embryo-foetal development  
Species: Monkey  
Application Route: Ingestion  
Developmental Toxicity: LOAEL: 2 mg/kg body weight  
Result: Teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Finasteride:

Exposure routes : Ingestion  
Target Organs : Testis  
Assessment : Causes damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Cellulose:

Species : Rat  
NOAEL :  $\geq 9,000$  mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days

#### Starch:

Species : Rat  
NOAEL :  $\geq 2,000$  mg/kg  
Application Route : Skin contact  
Exposure time : 28 Days  
Method : OECD Test Guideline 410

#### Finasteride:

Species : Rat  
NOAEL : 20 mg/kg

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

LOAEL : 40 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

Species : Dog  
NOAEL : 45 mg/kg  
Application Route : Oral  
Exposure time : 1 yr  
Target Organs : Testis

### Aspiration toxicity

Not classified based on available information.

### Experience with human exposure

#### Components:

##### **Finasteride:**

Ingestion : Symptoms: breast tenderness, breast enlargement, impotence, lip swelling, skin rash

## 12. ECOLOGICAL INFORMATION

### Ecotoxicity

#### Components:

##### **Cellulose:**

Toxicity to fish : LC50 (*Oryzias latipes* (Japanese medaka)): > 100 mg/l  
Exposure time: 48 h  
Remarks: Based on data from similar materials

##### **Finasteride:**

Toxicity to fish : LC50 (*Oncorhynchus mykiss* (rainbow trout)): 20.4 mg/l  
Exposure time: 96 h  
Method: FDA 4.11

Toxicity to daphnia and other aquatic invertebrates : EC50 (*Daphnia magna* (Water flea)): 17.8 mg/l  
Exposure time: 48 h  
Method: FDA 4.08

Toxicity to algae/aquatic plants : NOEC (*Pseudokirchneriella subcapitata* (green algae)): 49 mg/l  
Exposure time: 14 h  
Method: FDA 4.01

Toxicity to fish (Chronic toxicity) : NOEC (*Oryzias latipes* (Orange-red killifish)): 0.05 mg/l  
Exposure time: 105 d

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.12 mg/l  
Exposure time: 21 d  
Method: OECD Test Guideline 211

M-Factor (Chronic aquatic toxicity) : 1

### Persistence and degradability

#### Components:

##### Cellulose:

Biodegradability : Result: Readily biodegradable.

##### Finasteride:

Biodegradability : Result: Not readily biodegradable.  
Biodegradation: 0 %  
Exposure time: 7 d  
Method: FDA 3.11

Stability in water : Hydrolysis: 0 %(5 d)  
Method: FDA 3.09

### Bioaccumulative potential

#### Components:

##### Finasteride:

Partition coefficient: n-octanol/water : log Pow: 3.57

##### Mobility in soil

No data available

##### Other adverse effects

No data available

## 13. DISPOSAL CONSIDERATIONS

### Disposal methods

Waste from residues : Do not dispose of waste into sewer.  
Dispose of in accordance with local regulations.  
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.  
If not otherwise specified: Dispose of as unused product.

## 14. TRANSPORT INFORMATION

### International Regulations

UNRTDG

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

---

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Finasteride)  
Class : 9  
Packing group : III  
Labels : 9  
Environmentally hazardous : yes

### IATA-DGR

UN/ID No. : UN 3077  
Proper shipping name : Environmentally hazardous substance, solid, n.o.s. (Finasteride)  
Class : 9  
Packing group : III  
Labels : Miscellaneous  
Packing instruction (cargo aircraft) : 956  
Packing instruction (passenger aircraft) : 956  
Environmentally hazardous : yes

### IMDG-Code

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Finasteride)  
Class : 9  
Packing group : III  
Labels : 9  
EmS Code : F-A, S-F  
Marine pollutant : yes

### Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

### National Regulations

#### GB 6944/12268

UN number : UN 3077  
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Finasteride)  
Class : 9  
Packing group : III  
Labels : 9  
Marine pollutant : no

### Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

### 15. REGULATORY INFORMATION

#### National regulatory information

##### Law on the Prevention and Control of Occupational Diseases

##### Regulation on the Administration of Precursor Chemicals

Catalogue and Classification of Precursor Chemicals : Not listed

##### Yangtze River Protection Law

This product does not contain any dangerous chemicals prohibited for inland river transport.

##### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

### 16. OTHER INFORMATION

Revision Date : 2024/04/06

#### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Date format : yyyy/mm/dd

#### Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

CN OEL : Occupational exposure limits for hazardous agents in the workplace - Chemical hazardous agents.

ACGIH / TWA : 8-hour, time-weighted average

CN OEL / PC-TWA : Permissible concentration - time weighted average

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Or-

# SAFETY DATA SHEET

according to GB/T 16483 and GB/T 17519



ORGANON

## Finasteride (3.25%) Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2023/09/30
1.14	2024/04/06	2160725-00015	Date of first issue: 2017/11/09

---

ganisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

### Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN